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| INTRODUC TI ON
The first human heart transplant was performed at the Groote Schuur Hospital in Cape Town on December 3, 1967. 1 Since then, this therapy has gained importance for the treatment of end-stage heart failure, both in adult and in pediatric patients. 2, 3 Increasing survival rates, associated with tailored immunosuppression, are considered to be responsible for this trend. 4, 5 Nowadays, HTx is an established treatment option for terminal heart failure in children. 6, 7 In 2014, about 11 000 pediatric Htxs worldwide were registered by the ISHLT. 7 However, long waiting times for a suitable pediatric donor organ underline the importance of optimizing therapy for patients on the wait list. Thus, mechanical circulatory support is of increasing use. 4, 7 VAD are able to bridge time until transplantation (BTT), or in some cases, until recovery (BTR). According to the ISHLT, nearly 30% of pediatric patients treated for terminal heart failure between 2009 and 2015 needed an assist device as bridge to transplantation. 5 Despite satisfactory initial results of this therapy, long-term consequences should be assessed. 8, 9 Assist device implantations, as well as cardiac transplantations and prolonged waiting times, can have a severe impact on the psychological and physiological development, leading to a limited integration of young adults into their educational, professional, and social environments. [9] [10] [11] [12] [13] Risk factors for neurological and cognitive impairment around this therapy concept can be classified as preoperative (such as cerebral hypoperfusion due to congestive heart failure), intra-operative (eg, due to extracorporeal circulation and analgesic drugs), and postoperative (eg, cerebral hypoperfusion and immunosuppressive drugs). [14] [15] [16] [17] [18] Further, VAD therapy poses additional risks due to the device implantation, required anticoagulation, and increased risk for thrombosis, but also potential benefits for the preservation of intellectual function. 13, [19] [20] [21] Therefore, the aim of this study is to investigate motor outcomes and executive functioning, as well as the HRQoL in children, adolescents, and young adults after VAD and Htx.
| PATIENTS AND ME THODS
All pediatric patients who received an assist device (BTT or BTR) at the LMU Munich, University Hospital between 1992 and 2016 were included and their medical records were reviewed.
To assess the motor and executive functioning outcomes, as well as the HRQoL, a protocol, including the specific tests outlined below, was developed.
This study was approved by the local institutional ethics committee and was executed according to the Declaration of Helsinki (1997) and subsequent revisions. Informed consent was obtained from all individual participants included in the study. Our patients were examined in the setting of our outpatient clinic during a routine follow-up. Intraobservational and interobservational variability was assessed by comparing results. Reliability was reported and is supported by previous studies. [22] [23] [24] [25] [26] [27] [28] 
| Assessment of MND
To assess motor function we utilized testing for MND. It is based on the Touwen Infant Neurological Examination, originally developed to monitor development in children. 29 This standardized neurodevelopmental examination is mainly part of clinical practice, but it is also used in study protocols, particularly in neonatology, to investigate and follow up on the development of preterm infants and newborns at risk. 30 The examination for MND includes standard items such as reflexes, cranial nerve health motor and sensory functioning, body tone, and coordination. It contains eight domains of appreciation: posture and muscle tone, reflexes, choreiform dyskinesia, coordination, fine manipulative ability, associated movements, sensory deficits, and cranial nerve function. It includes for these items an age-specific appreciation of the child's performance during examination with special attention given to involuntary and associated movements. Each domain is assessed by several different tests and can be appreciated separately, according to the child's performance.
Subsequently, a distinction can be made between a normal finding, and a simple or a complex MND, based on the number of dysfunctional domains.
The accuracy and validity of this method were reported in previous studies, showing a good to excellent test-retest reliability. 25, 30, 31 There are two different forms of MND: simple and complex MND. This classification is based on the number of dysfunctions present (before the onset of puberty) or on the type of dysfunction (after the onset of puberty). A simple MND is considered to be in the range of a "normal" neurological performance and is also described as "minor neurological difference". In contrast, the presence of a complex MND reflects a neurological dysfunction and, regarding developmental aspects, is strongly related to learning and behavioral disorders.
We used the MND examination forms to assess patients aged 6 years and older to detect even slight neurological deviations. All patients or the parents of underage children signed an informed K E Y W O R D S cognitive outcome, executive functioning, health-related quality of life, motoric outcome, neurological outcome, Pediatric heart transplantation, ventricular assist device consent form for video documentation, in order to validate the results by a pediatric neurologist (LG).
| Epitrack ®
To assess the executive functioning of our patients, the Epitrack ® test was used. This is a cognitive test instrument originally developed as a 15-minute screening tool for the detection and tracking of cognitive side effects of both antiepileptic drugs and seizures in patients with epilepsy. 32 The EpiTrack ® test comprises six subtests; these are borrowed from other well-established tests: The German "Kurztest für cerebrale Insuffizienz" (subtest 1); the Trail Making Test , and (f) inverted digit span (working memory). 33 The EpiTrack ® test allows for the quick and simple screening of attention and executive functioning, including working memory. 26, 32 The reliability of the Epitrack ® test has been reported in previous studies, examining 277 (Epitrack ® junior) and 689 (Epitrack ® adult) patients in total. Some of these patients were retested after a few months, achieving a retest reliability of r = 0.78 and r = 0.90. 22, 26, 27 This test has been described in previous studies as a valid and reliable screening tool for the assessment of executive functioning. 26 The Epitrack ® test is available in two different versions: a junior (for children from 6 to 18 years of age) and an adult version.
Total scores in the junior version range from 6 to 56 points and are classified into four categories: good (≥36 points), average (31) (32) (33) (34) (35) points), borderline (29-30 points), and impaired (≤28 points). The adult version is scored within 9-49 points, as good (≥39 points), average (32-38 points), borderline (29-31 points), and impaired (≤28 points).
As the Epitrack ® test is time-efficient, shown to be a sensitive instrument for detecting problems with attention and executive functions, and has also been used in research fields beside epilepsy and schizophrenia, we decided to include the Epitrack ® test in our study. [33] [34] [35] 
| Assessment of quality of life
The QoL of children, adolescents, and young adults was assessed with the self-and proxy version of the Kidscreen-52 questionnaire (≤18 years). It was completed by the patient (minimum age: 8 years) and their parents (for patients of all ages). The EQ-5D-5L was also used, completed by the patients themselves if patients were adults at the time of follow-up.
| The Kidscreen-52 Questionnaire
The Kidscreen-52 was developed by the Kidscreen Group Europe as a generic and cross-cultural instrument, which is available in 32 languages (including German). 23, 36, 37 It consists of 10 dimensions: children and adolescents (8-18 years) available. 37 The reliability and validity of the Kidscreen questionnaire have been reported in previous studies. 23, 37 
| EQ-5D-5L
The EQ-5D-5L was developed by the EuroQoL Group as a standardized, generic measure of health status. 38 It consists of a descriptive system and a VAS. indicating full health). The reliability and validity of the EQ5D-5L questionnaire were reported in previous studies. [39] [40] [41] [42] It also has been assessed via the examination of patients with several different diseases in numerous countries and is used in the INTERMACS report, which describes the QoL of patients treated with assist devices. [43] [44] [45] [46] [47] 
| Statistical analysis
Statistical analysis of the data was performed with IBM SPSS Statistic software (version 24. IBM Corporation) and Microsoft Excel (version 12.1.0 for Mac). Analysis of the Kidscreen data was performed according to the instruction on the Kidscreen Manual. 48 The EQ-5D-5L index values were calculated with the EQ-5D-5L Crosswalk Index Value Calculator, which can be downloaded from the EuroQoL website (https ://euroq ol.org/eq-5d-instr ument s/eq-5d-5l-about/ valua tion-stand ard-value-sets/cross walk-index-value-calcu lator/ ). 49 Descriptive analysis was carried out for the entire cohort with continuous variables reported as percentage, mean, median, range, and standard deviation. P-values were calculated using the nonparametric Wilcoxon signed-rank test.
| RE SULTS

| Patients' characteristic and clinical data
Out of a total of 145 pediatric heart transplant patients, 39 patients 
| Neurological examination using the assessment for MND
The MND assessment is considered to be an excellent tool for detecting and classifying neurological dysfunction in seemingly healthy patients. 50 The MND assessment was performed on a total of 13 patients, ≥6 years, without apparent neurological deficit, in order to detect even slight neurological impairment. Eleven patients had normal examination results, 1 patient showed a simple MND, and 1 patient presented with a complex MND. A majority of patients scored an "average" result (n = 6), followed in frequency by the results "Impaired" (n = 4), "borderline" (n = 3), and "good" (n = 2). The results of the Epitrack ® test are presented in Table 3 .
| Epitrack ®
| Quality of life
| Kidscreen-52
A total of 7 children and 11 parents completed the self-and proxy version of the Kidscreen-52 Questionnaire. Children estimated their HRQoL similar to the age-matched German reference population, without significant difference (Table 4 ). In the proxy version (parents estimating QoL of their children), the score in the autonomy scale was significantly lower compared to the German reference sample. The difference in the responses to the financial resources scale between self-and proxy versions of the questionnaire did not reach significance.
Parents rated all other scales similar to the German reference population, meaning that they do not perceive their child to suffer from any disadvantages in daily life, compared to healthy children (see Table 5 ).
The comparison of the HRQoL scores given by patients themselves (n = 7) to scores given by parents (n = 7) is presented in Figure 2 and Table 6 . Parents estimated social acceptance and bullying to be a significantly larger burden than their children, while children scored their financial resources significantly higher. 
| EQ-5D-5L
Eight adult patients (≥18 years) completed the EQ-5D-5L questionnaire. Answers to the descriptive part of the EQ-5D-5L questionnaire are provided in Table 7 . Calculated index values in comparison with a German reference population are shown in 
| D ISCUSS I ON
After over 50 years of pediatric Htx, this therapy option has become well established. 51 The VAD treatment has also grown in importance over the years, in both the pediatric and adult fields, and now represents an often used bridge-to-transplant or bridge-to-recovery option. 52 It is therefore critical to assess possible complications and long-term outcome of these therapies.
Possible side effects of Htx and of assist device therapy are neurological events. 52 The implantation of an assist device or a Htx requires the use of a cardiopulmonary bypass, with known potential risks for embolic stroke. 15, 18 Further, during assist device therapy, a strict anticoagulation protocol must be carried out. This leads to an increased risk for anticoagulation drug-associated complications. These can manifest as acute bleeding, stroke, and further neurological dysfunction.
Besides acute events, it is also conceivable that these therapies may affect long-term motor and executive functioning.
HRQoL is an important outcome indicator for children with neurological disabilities and might be influenced, among others, by motor functioning and psychosocial domains like cognition, behavior, and education. 53, 54 In children with VAD and Htx, outcome studies often focus on technical details, survival, and medication. [55] [56] [57] [58] Therefore, we showed that, among several potential factors, a low Apgar score, history of sepsis, and a long duration of hospitals stay correlated with an increased risk for a simple MND. 60 However, these results are not directly comparable to ours due to the investigation of different diseases and risk factors. Nonetheless, compared to results of these and further studies, our findings show good results in the MND examination of this cohort. They are comparable to those of a healthy population. 50, [59] [60] [61] On the one hand, studies of the motor and executive functioning of patients treated with a VAD suggest a benefit of this therapy due to better cerebral perfusion. 21 and Htx are still associated with a high risk of brain injury and thus neurological complications. VanderPluym et al previously described neuroimaging results, obtained during and after VAD therapy, screening for brain injuries in children under 6 years old, bridged with the Berlin Heart excor ® . 75% of patients were reported to show brain injury during neuroimaging at some point in their life, while 31% were found to have brain injuries during VAD therapy. In this study, abnormal neuroimaging generally correlated with an abnormal neurological and physical examination. It was also found that abnormal physical examination often correlated with lower IQ scores.
Only 2 patients (out of 10) had abnormal neuroimaging results with a neurological and physical examination within normal limits. 64 Neurological impairment may be of a motoric nature, but can also affect executive functioning. With this in mind, the cognitive state of our patients was examined. Though the Epitrack ® was originally designed to monitor attention and executive functioning in patients with epilepsy, it is a promising screening test in patients with other neurological disorders, also. 26 In clinical practice, detected deficits should be further investigated through a comprehensive neuropsychological examination, while considering the context of the child´s educational and social performance.
In this cohort, Epitrack ® testing revealed slight impairments in some cases; however, results generally indicated quite positive results considering the high risk for neurological events during this therapy. On average, children performed 7.36% and adults 13.82% lower than the reference population. 22, 27 Other studies about the cognitive outcome after VAD therapy are very promising. Chinnock et al described the developmental outcome of children after Htx as within a low to average range. 65 Jahnukainen et al found that the cognitive outcome of children bridged with an assist device was not worse than that of children who did not need an assist device before their Htx. 9 As neurological impairment and cognition problems can greatly affect patients´ lives, a main objective of this study was to examine patients' subjective assessment about their QoL.
There are few studies evaluating HRQ oL after Htx in childhood or adolescence (with or without VAD as a bridge to transplantation). [66] [67] [68] [69] In this study, patients reported an average daily QoL be considered that the age range of our patients is very variable. It could therefore be interesting to analyze results of future studies in the context of patient age.
In most studies on assist device therapy and Htx, the main focal points are survival and general health outcomes. Especially, the executive and motor outcomes are decisive for the integration of a child into its' educational, later professional, and social environment. Therefore, the Epitrack ® testing in particular, which is easy and quick to perform, should be an inherent part of the post-Htx follow-up, in order to detect executive deficits as soon as possible. Further studies for exploring potential follow-up programs are warranted.
| CON CLUS ION
The main objective of this study was to examine the motoric and executive functioning outcomes, as well as the HRQoL of patients who received an assist device as a bridge to transplantation or BTR at the department of pediatric cardiology between 1992 and 2016 at the university hospital in Munich. To assess this, we used a battery of tests composed of the MND neurological examination, Epitrack ® test, and Kidscreen 52/EQ-5D-5L QoL questionnaires.
Our results suggest, that in children with VAD for bridge to transplantation or BTR, overall executive and motor development is encouragingly strong, which may be reflected in a high QoL. Most patients seem to achieve normally functioning social, academic, and professional lives. Further studies to confirm these findings are warranted.
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